9 Meters Biopharma, Inc.
News
Brokerages Set 9 Meters Biopharma, Inc. (NASDAQ:NMTR) Price Target at $44.18
Zolmax Shares of 9 Meters Biopharma, Inc. (NASDAQ:NMTR Get Rating) have earned an average recommendation of Hold from the six analysts that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. ...\n more…
9 Meters Biopharma, Inc. (NASDAQ:NMTR) Receives $44.18 Average Target Price from Brokerages
Ticker Report 9 Meters Biopharma, Inc. (NASDAQ:NMTR Get Rating) has received an average rating of Hold from the six ratings firms that are covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the ...\n more…
William Blair Comments on 9 Meters Biopharma, Inc.'s Q2 2023 Earnings (NASDAQ:NMTR)
Ticker Report 9 Meters Biopharma, Inc. (NASDAQ:NMTR Get Rating) William Blair dropped their Q2 2023 earnings per share estimates for 9 Meters Biopharma in a research report issued to clients and investors on Tuesday, May 30th. William Blair analyst T. Lugo now anticipates that the company will ...\n more…
9 Meters Biopharma, Inc. to Post Q2 2023 Earnings of ($1.06) Per Share, William Blair Forecasts (NASDAQ:NMTR)
Zolmax 9 Meters Biopharma, Inc. (NASDAQ:NMTR Get Rating) Equities researchers at William Blair lowered their Q2 2023 earnings per share estimates for shares of 9 Meters Biopharma in a research report issued on Tuesday, May 30th. William Blair analyst T. Lugo now expects that the company will post earnings ...\n more…
9 Meters Biopharma (NASDAQ:NMTR) versus Iterum Therapeutics (NASDAQ:ITRM) Head-To-Head Review
Ticker Report 9 Meters Biopharma (NASDAQ:NMTR Get Rating) and Iterum Therapeutics (NASDAQ:ITRM Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, ...\n more…
9 Meters Biopharma slips 16% as CEO departs
SeekingAlpha.com: All News 9 Meters Biopharma (NMTR) lost ~16% on Tuesday after announcing the immediate resignation of its President and Chief Executive Officer John Temperato. Read more here.\n more…